Arcus Biosciences (RCUS) Capital Expenditures (2017 - 2026)

Arcus Biosciences' Capital Expenditures history runs 9 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• In Q4 2025, Capital Expenditures rose 116.67% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (up 104.55% YoY), while the FY2025 annual figure was $2.0 million, up 109.09% from the prior year.
• Capital Expenditures for Q4 2025 stood at $1.0 million, roughly flat from $1.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $12.0 million in Q4 2023, with the low at -$20.0 million in Q3 2024.
• The 5-year median for Capital Expenditures is $2.0 million (2022), against an average of $764705.9.
• Peak annual rise in Capital Expenditures reached 1232.06% in 2021, while the deepest fall reached 4298.65% in 2021.
• Arcus Biosciences' Capital Expenditures stood at -$1.6 million in 2021, then soared by 224.61% to $2.0 million in 2022, then soared by 500.0% to $12.0 million in 2023, then slumped by 150.0% to -$6.0 million in 2024, then soared by 116.67% to $1.0 million in 2025.
• Business Quant data shows RCUS's Capital Expenditures at $1.0 million in Q4 2025, $1.0 million in Q1 2025, and -$6.0 million in Q4 2024.